Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms

Clinica Chimica Acta

Volumn 372, Issue 1-2, 2006, Pages 195-198

  Aquilante, Christina L ^a   Langaee, Taimour Y ^b   Anderson, Peter L ^a   Zineh, Issam ^b   Fletcher, Courtney V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

CYP3A5; Pharmacogenetic; Pyrosequencing

Indexed keywords

CYTOCHROME P450 3A5;

ARTICLE; CHEMICAL REACTION; DNA POLYMORPHISM; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BASE SEQUENCE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; GENOTYPE; LIVER; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 33747836010     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.02.046     Document Type: Article

References (15)

1. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
2. Schuetz E.G., Relling M.V., Kishi S., et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 56 (2004) 159
3. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294
4. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
5. Lin Y.S., Dowling A.L., Quigley S.D., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (2002) 162-172
6. Williams J.A., Cook J., and Hurst S.I. A significant drug-metabolizing role for CYP3A5?. Drug Metab Dispos 31 (2003) 1526-1530
7. Xie H.G., Wood A.J., Kim R.B., Stein C.M., and Wilkinson G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272
8. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363-365
9. Langaee T., and Ronaghi M. Genetic variation analyses by pyrosequencing. Mutat Res 573 (2005) 96-102
10. Pourmand N., Elahi E., Davis R.W., and Ronaghi M. Multiplex pyrosequencing. Nucleic Acids Res 30 (2002) e31
11. Garsa A.A., McLeod H.L., and Marsh S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med Genet 6 (2005) 19
12. Katz D.A., Grimm D.R., Cassar S.C., et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 75 (2004) 516-528
13. Marsh S., King C.R., Garsa A.A., and McLeod H.L. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 311 (2005) 97-114
14. Aquilante C.L., Lobmeyer M.T., Langaee T.Y., and Johnson J.A. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 24 (2004) 720-726
15. Palmieri O., Toth S., Ferraris A., et al. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin Chem 49 (2003) 1675-1679